Clinical Trials Logo

Clinical Trial Summary

Tinea capitis is a dermatophyte infection of the scalp hair follicles, which occurs primarily in children. Hair loss, hair breakage, scaling, plus various degrees of erythema, pustules and pruritus are the primary clinical signs which can be associated with tinea capitis. The infection is caused by a relatively small group of dermatophytes in the genera Trichophyton and Microsporum.

Terbinafine hydrochloride is a synthetic allylamine derivative antifungal agent. This study will evaluate the efficacy and safety of terbinafine in children with tinea capitis.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT00117767
Study type Interventional
Source Novartis
Contact
Status Completed
Phase Phase 3
Start date June 2004

See also
  Status Clinical Trial Phase
Completed NCT00224926 - The Natural Course of Trichophyton Tonsurans Carriage and Infection: A Molecular and Biochemical Evaluation N/A
Completed NCT04144491 - Effect of L. Rhamnosus Yoba on RTI and Other Health Outcomes Among Children (3-6 Years) in Uganda N/A
Completed NCT00645242 - A Study Of Diflucan In Children With Ringworm Of The Scalp Phase 3
Completed NCT02725255 - Design and Clinical Evaluation of a School Meal With Deworming Properties Phase 2/Phase 3
Completed NCT02550496 - Evaluation of Trichoscopy in the Diagnosis of Tinea Capitis N/A
Completed NCT00127868 - Selenium Sulfide, Ketoconazole and Ciclopirox Shampoo as Additional Treatments for Tinea Capitis (Scalp Ringworm) N/A
Completed NCT00117754 - Terbinafine Compared to Griseofulvin in Children With Tinea Capitis Phase 3
Withdrawn NCT02658292 - Safety and Efficacy of NAFT900 in Children With Tinea Capitis Phase 2